KLRK1 and acute myeloid leukemia: Previous studies with several solid tumor and AML cells have shown that treatment with decitabine could up-regulate NKG2D ligand expression which contributes to increased NK cell-mediated cytolytic activity12, 13, 14, 34; however, this effect was weak when decitabine was used as a monotherapy13.